Matrix Hyaluronan-activated CD44 Signaling Promotes Keratinocyte Activities and Improves Abnormal Epidermal Functions
Overview
Authors
Affiliations
Hyaluronan (HA), a major component of the extracellular matrix, is enriched in skin tissues, particularly the epidermis. HA binds to a ubiquitous, abundant, and functionally important family of cell surface receptors, CD44. This article reviews the current evidence for HA/CD44-mediated activation of RhoGTPase signaling and calcium mobilization, leading to the regulation of keratinocyte activities and various epidermal functions. It further discusses the role of HA-mediated CD44 interactions with unique downstream effectors, such as RhoGTPases (RhoA and Rac1), Rho-kinase, protein kinase-Nγ, and phosphoinositide-specific phospholipases (phospholipases Cε and Cγ1) in coordinating certain intracellular signaling pathways, such as calcium mobilization, phosphatidylinositol 3-kinase-AKT activation, cortactin-actin binding, and actin-associated cytoskeleton reorganization; generating the onset of important keratinocyte activities, such as cell adhesion, proliferation, migration, and differentiation; and performing epidermal functions. Topical application of selective HA fragments (large versus small HA) to the skin of wild-type mice (but not CD44 knockout mice) improves keratinocyte-associated epidermal functions and accelerates permeability barrier recovery and skin wound healing. Consequently, specific HA fragment (large versus small HA)-mediated signaling events (through the CD44 receptor) are required for keratinocyte activities, which offer new HA-based therapeutic options for patients experiencing epidermal dysfunction and skin damage as well as aging-related skin diseases, such as epidermal thinning (atrophy), permeability barrier dysfunction, and chronic nonhealing wounds.
Ariyoshi W, Takeuchi J, Mitsugi S, Koga A, Nagai-Yoshioka Y, Yamasaki R Biomedicines. 2025; 13(2).
PMID: 40002789 PMC: 11852791. DOI: 10.3390/biomedicines13020376.
Yao C, Yang S, Shieh M, Young T Polymers (Basel). 2025; 17(3).
PMID: 39940551 PMC: 11819680. DOI: 10.3390/polym17030350.
Thonthula S, Sousa S, Dubuis A, Boudah S, Mehta R, Singh A Int J Mol Sci. 2024; 25(23).
PMID: 39684479 PMC: 11641536. DOI: 10.3390/ijms252312770.
The function of the inter-alpha-trypsin inhibitors in the development of disease.
Zhang X, Zhang X, Guo L, Bai Y, Tian Y, Luo H Front Med (Lausanne). 2024; 11:1432224.
PMID: 39149600 PMC: 11325723. DOI: 10.3389/fmed.2024.1432224.
Growth factors and growth factor gene therapies for treating chronic wounds.
Mullin J, Rahmani E, Kiick K, Sullivan M Bioeng Transl Med. 2024; 9(3):e10642.
PMID: 38818118 PMC: 11135157. DOI: 10.1002/btm2.10642.